clinical trial · NCT07842172
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Neuroendocrine NeoplasmGastroenteropancreatic Neuroendocrine NeoplasmSomatostatin Analogue(s)
brief summary
This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with Peptide Receptor Radionuclide Therapy (PRRT) (ethanol-stabilized Lu-177 dotatate).
started
Nov 2, 2026
primary completion
Nov 30, 2034
completion
Nov 30, 2034
last updated
Nov 6, 2026
official title
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Nonfunctional Neuroendocrine Neoplasms (REMAIN Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol